ENGN
NASDAQ HealthcareenGene Holdings Inc. - Common Stock
Biotechnology
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
�� 市场数据
| 价格 | $8.07 |
|---|---|
| 成交量 | 842,822 |
| 市值 | 540.60M |
| 贝塔系数 | -0.050 |
| RSI（14日） | 82.7 超买 |
| 200日均线 | $7.16 |
| 50日均线 | $8.25 |
| 52周最高 | $12.25 |
| 52周最低 | $2.65 |
| Forward P/E | -4.25 |
| Price / Book | 1.92 |
🎯 投资策略评分
ENGN 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (79/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (2/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ENGN in your text
粘贴任何文章、记录或帖子 — 工具将提取 ENGN 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.